Clinical trials represent a cornerstone of modern clinical research, systematically investigating the safety, efficacy and overall impact of medical interventions. Equally important is the ...
While policies and regulations on ClinicalTrials.gov registration and reporting aim to increase the availability of information to the public about clinical trials, requirements vary depending on the ...
Results From the First 25,000 Participants Expected in the Second Half of 2025 GRAIL Completes Final Study Visits for the NHS-Galleri Trial; Final Results Expected in 2026 PATHFINDER 2 is a ...
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (OKYO) (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat ...
A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate ...
– New data presented at AASLD The Liver Meeting. Investor conference call November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET – SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today ...
With 2026 set to be a banner year for M&A as buyers facing patent cliffs compete for a limited pool of late-stage assets ( [3]) , companies demonstrating disciplined pivotal execution and FDA ...
KØBENHAVN, DK / ACCESS Newswire / January 21, 2026 / FluoGuide A/S ("FluoGuide" or the "Company")(STO:FLUO), a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today ...
NEW YORK--(BUSINESS WIRE)--In 2025, Bonerge initiated a clinical trial (Registration #NCT06990256) investigating the effects of Urolithin A and Fisetin on sleep quality, targeting sleep disorders ...
OKYO Pharma’s new CEO Robert Dempsey joined Steve Darling from Proactive to announce that the company has completed a ...
GRAIL Completes Enrollment of More Than 35,000 Participants in the PATHFINDER 2 Study; Results From the First 25,000 Participants Expected in the Second Half of 2025 GRAIL Completes Final Study Visits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results